Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Buys $19,958.40 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Otis W. Brawley acquired 35,640 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $0.56 per share, for a total transaction of $19,958.40. Following the purchase, the director now directly owns 35,640 shares of the company’s stock, valued at approximately $19,958.40. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Lyell Immunopharma Trading Down 0.0 %

NASDAQ:LYEL opened at $0.46 on Friday. The company has a 50-day moving average of $0.60 and a 200-day moving average of $0.84. The firm has a market cap of $137.22 million, a price-to-earnings ratio of -0.59 and a beta of -0.41. Lyell Immunopharma, Inc. has a twelve month low of $0.44 and a twelve month high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million during the quarter. On average, research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently modified their holdings of LYEL. Centiva Capital LP purchased a new position in Lyell Immunopharma in the 3rd quarter worth about $31,000. Graham Capital Management L.P. acquired a new position in shares of Lyell Immunopharma in the fourth quarter worth about $33,000. RPO LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter worth approximately $42,000. Intech Investment Management LLC acquired a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $52,000. 66.05% of the stock is owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.